CONNECT announces winners of the Life Sciences Capital Competition

Posted on Feb 1, 2013 in CONNECT News, CONNECT Portfolio Company News, News | 0 comments

This week, a distinguished panel of industry judges selected five winning companies in CONNECT’s Life Sciences Capital Competition. The winners of the Capital Competition become CONNECT Portfolio Companies. The Portfolio companies have undergone a rigorous pre-screen, screening and mentoring process. DermTech, Eolas Therapeutics, JET Surgical, and Nasseo, Inc. have been awarded the opportunity to present their technologies to a group of VCs at the March 14 Capital Roadshow in Palo Alto.

Other Capital Competition winners include GIRx, who will present at an upcoming Deal Network to high net worth individual investors and local VCs. The Life Sciences Capital Competition is sponsored by Morrison & Foerster LLP, Cushman & Wakefield, Inc. and Ernst & Young LLP. Event partners include Merck Research Laboratories and Pfizer, Inc.

The CONNECT Get Coached to Get Capital program seeks out radical innovation in the Southern California start-up scene. Winners were selected by a dynamic group of industry experts from Biological Dynamics; Biomatrica; BioMed Realty; bioTheranostics; Celgene Corporation; FinistereVentures, LLC; MDNA Consulting, Inc.; MediAccess Solutions, LLC; Pfizer, Inc.; Santarus, Inc.; Senomyx, Inc.; Targeson, Inc.; Tech Coast Angels; Tigris Ventures LLC;.

The Life Sciences category is for companies with diagnostics, bio-markers, instrumentation, microbiology, molecular biology, therapeutics, pharmaceuticals, and mHealth.

More about the portfolio companies

DermTech is revolutionizing the detection and diagnosis of dermatologic conditions using a patented non-invasive biopsy technology to analyze gene expression in the skin.

Eolas Therapeutics is a therapeutic development company committed to treating diseases of addiction and anxiety – its lead programs are compounds to treat nicotine and cocaine addiction.

GIRx has a novel way to treat diabetes using agents that act from within the GI tract to cause systemic release of key metabolic hormones, while the agents themselves are not systemically distributed, thereby reducing or eliminating the opportunity for adverse effects.

JET Surgical is a regenerative medicine company that is developing a novel and proprietary product that will both improve the safety and recovery time of corneal wound healing in laser vision correction.

Nasseo, Inc. is a medical device company that has developed dental and orthopedic implant technology with a higher success rate than current dental implants. Nasseo’s first product, The TiArray™ dental implant system, integrates its proprietary implant surface modification technology to provide a greater bone-to-implant bonding strength and lowered inflammatory responses.

To get more information about CONNECT’s Get Coached to Get Capital Program, click here.

If you are an investor and interested in attending the Capital Roadshow please contact Orlee Dykan at